ArticleBMC surgery2026
Prevalence and determinants of low anterior resection syndrome following rectal cancer resection: a cross-sectional study.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Sphincter-preserving surgery after conversion therapy and longitudinal recovery of bowel function in ultra-low rectal cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow anterior resection syndrome (LARS) is a debilitating bowel dysfunction that frequently follows sphincter-preserving surgery for rectal cancer. This study aimed to assess the prevalence of LARS and identify its associated determinants in a cohort of rectal cancer survivors.
methodsIn this cross-sectional study, patients who underwent sphincter-preserving surgery for rectal cancer at least one year prior were recruited from the Shiraz Colorectal Cancer Surgery (SCORCS) registry. Based on symptom severity assessed via the LARS score, patients were categorized as having no, minor, or major LARS. Multivariable logistic regression analyses were employed to identify determinants associated with any LARS (minor or major vs. none) and major LARS (vs. no and minor combined).
resultsThe prevalence of LARS was 53.7% (58/108), comprising minor LARS in 31.5% and major LARS in 22.2% of patients. Multivariable analysis identified older age (odds ratio [OR]: 1.04, 95% confidence interval [CI]: 1.01-1.08) and neoadjuvant radiotherapy (OR: 4.38, 95% CI: 1.54-12.45) as determinants for any LARS. For major LARS, independent determinants were older age (OR: 1.05, 95% CI: 1.01-1.10) and female sex (OR: 2.97, 95% CI: 1.02-8.60). There was no significant difference in quality-of-life domains across LARS severity groups.
conclusionThis study confirms a high prevalence of LARS among rectal cancer survivors. Neoadjuvant radiotherapy, older age, and female sex were identified as determinants of LARS in this cohort; however, due to the study's limitations, the findings should be interpreted cautiously.
Indexed as
Identifiers
42482251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.